Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44


The antidepressant sertraline downregulates Akt and has activity against melanoma cells.

Reddy KK, Lefkove B, Chen LB, Govindarajan B, Carracedo A, Velasco G, Carrillo CO, Bhandarkar SS, Owens MJ, Mechta-Grigoriou F, Arbiser JL.

Pigment Cell Melanoma Res. 2008 Aug;21(4):451-6. doi: 10.1111/j.1755-148X.2008.00481.x.


Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice.

Gil-Ad I, Zolokov A, Lomnitski L, Taler M, Bar M, Luria D, Ram E, Weizman A.

Int J Oncol. 2008 Aug;33(2):277-86.


Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.

Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang SY, Robell K, Kahana JA, Geske RS, Kleymenova EV, Choudhry AE, Lai Z, Leber JD, Minthorn EA, Strum SL, Wood ER, Huang PS, Copeland RA, Kumar R.

Cancer Res. 2008 Apr 1;68(7):2366-74. doi: 10.1158/0008-5472.CAN-07-5783.


15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity.

Shin SW, Seo CY, Han H, Han JY, Jeong JS, Kwak JY, Park JI.

Clin Cancer Res. 2009 Sep 1;15(17):5414-25. doi: 10.1158/1078-0432.CCR-08-3101. Epub 2009 Aug 18.


ExcisaninA, a diterpenoid compound purified from Isodon MacrocalyxinD, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway.

Deng R, Tang J, Xia LP, Li DD, Zhou WJ, Wang LL, Feng GK, Zeng YX, Gao YH, Zhu XF.

Mol Cancer Ther. 2009 Apr;8(4):873-82. doi: 10.1158/1535-7163.MCT-08-1080.


Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.

Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.

Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65. doi: 10.1007/s00280-008-0850-3. Epub 2008 Oct 19.


Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.


Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.

Cancer Res. 2009 Jul 15;69(14):5835-42. doi: 10.1158/0008-5472.CAN-08-4285. Epub 2009 Jul 7.


Pre-clinical assessment of A-674563 as an anti-melanoma agent.

Zou Y, Fan G, Wang X.

Biochem Biophys Res Commun. 2016 Aug 12;477(1):1-8. doi: 10.1016/j.bbrc.2016.03.020. Epub 2016 Mar 10.


Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis.

Tang C, Lu YH, Xie JH, Wang F, Zou JN, Yang JS, Xing YY, Xi T.

Anticancer Drugs. 2009 Apr;20(4):249-58. doi: 10.1097/CAD.0b013e328327d476.


Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo.

Chen H, Sun B, Pan S, Jiang H, Sun X.

Anticancer Drugs. 2009 Feb;20(2):131-40. doi: 10.1097/CAD.0b013e3283212ade.


Imatinib targeting of KIT-mutant oncoprotein in melanoma.

Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, Demetri GD, Widlund HR, Fisher DE, Hodi FS.

Clin Cancer Res. 2008 Dec 1;14(23):7726-32. doi: 10.1158/1078-0432.CCR-08-1144.


NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.

Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.


AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.

Byth KF, Thomas A, Hughes G, Forder C, McGregor A, Geh C, Oakes S, Green C, Walker M, Newcombe N, Green S, Growcott J, Barker A, Wilkinson RW.

Mol Cancer Ther. 2009 Jul;8(7):1856-66. doi: 10.1158/1535-7163.MCT-08-0836. Epub 2009 Jun 9.


Kaempferol induces cell death through ERK and Akt-dependent down-regulation of XIAP and survivin in human glioma cells.

Jeong JC, Kim MS, Kim TH, Kim YK.

Neurochem Res. 2009 May;34(5):991-1001. doi: 10.1007/s11064-008-9868-5. Epub 2008 Oct 24.


Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

Meng H, Yang C, Jin J, Zhou Y, Qian W.

Leuk Lymphoma. 2008 Oct;49(10):1954-62. doi: 10.1080/10428190802320368.


Nemorosone blocks proliferation and induces apoptosis in leukemia cells.

Díaz-Carballo D, Malak S, Freistühler M, Elmaagacli A, Bardenheuer W, Reusch HP.

Int J Clin Pharmacol Ther. 2008 Aug;46(8):428-39.


Supplemental Content

Support Center